Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alkermes plc - Ordinary Shares (NQ: ALKS )

29.71 -0.26 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega
Alkermes plc (NASDAQ: ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56 
Via Benzinga
Earnings Preview: Alkermes
Via Benzinga
Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor
From Sarissa Capital Management LP
Via Business Wire
Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
From Sarissa Capital Management LP
Via Business Wire
Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
Where Alkermes Stands With Analysts
Via Benzinga
Alkermes Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for Alkermes's Future
Via Benzinga
Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes
From Sarissa Capital Management LP
Via Business Wire
Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board
From Sarissa Capital Management LP
Via Business Wire
The Latest Analyst Ratings for Alkermes
Via Benzinga
A Preview Of Alkermes's Earnings
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Alkermes Earnings Preview
Via Benzinga
Analyst Ratings for Alkermes
Via Benzinga
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements
Via Benzinga
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
From Sarissa Capital Management LP
Via Business Wire
Alkermes Stock Sees Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance
Via Benzinga
Alkermes: Commercialization Program On Track, Sales Coming In Strong
The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance. 
Via Talk Markets
Alkermes Stock Sees Rising Relative Price Strength
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86. 
Via Investor's Business Daily
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. 
Via Investor's Business Daily
Alkermes's Return On Capital Employed Insights
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q3 sales of $252.36 million. Earnings fell to a loss of $63.97 million, resulting in a 112.28% decrease from last quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Upgrades 
Via Benzinga
Recap: Alkermes Q3 Earnings
Alkermes (NASDAQ:ALKS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Alkermes missed estimated... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
Upgrades 
Via Benzinga
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.26... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.